Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Clinical trial NCT05270044 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05270044
- Sponsor
- Pierre Fabre Medicament
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-02
- Primary completion
- 2027-03-31
- Enrollment
- 815
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.